Jerónimo B. A.
- Country
- Spain
- Department
- Rheumatology
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 61 of 102 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in treating Sjögren's Syndrome, focusing particularly on cases with moderate to severe systemic manifestations. Their research encompasses comprehensive evaluation of novel therapeutic approaches for managing this complex autoimmune condition.
- Systemic Disease Management
- Autoimmune Treatment Innovation
- Clinical Disease Assessment
Their expertise extends to evaluating systemic manifestations and disease activity in autoimmune conditions.
Therapeutic Development
The investigator's work centers on advancing treatment options for systemic autoimmune diseases, with particular attention to novel therapeutic agents targeting specific disease pathways.
- Treatment Efficacy Assessment
- Safety Profile Evaluation
- Disease Activity Monitoring
Their research focuses on evaluating therapeutic responses in patients with complex autoimmune manifestations.
Clinical Assessment
Specializing in systematic evaluation of disease progression and treatment outcomes in autoimmune conditions, with emphasis on measuring therapeutic effectiveness in systemic manifestations.
- Disease Activity Measurement
- Treatment Response Analysis
- Patient Outcome Assessment
Their work involves comprehensive monitoring of clinical responses in systemic autoimmune disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.